← Back to Search

Antiviral

Arm 1: low dose for COVID-19

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 3, 10 and 14
Awards & highlights

Study Summary

This trial aims to determine if PF-07817883 treatment can safely reduce the virus that causes COVID 19 in adults with symptoms.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 3, 10 and 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 3, 10 and 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Change from baseline in SARS-CoV-2 RNA level
Incidence of AEs leading to discontinuations.
Incidence of Serious Adverse Events (SAE)
+4 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 3: high doseExperimental Treatment1 Intervention
Group II: Arm 2: medium doseExperimental Treatment1 Intervention
Group III: Arm 1: low doseExperimental Treatment1 Intervention
Group IV: Arm 4: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07817883
2022
Completed Phase 2
~350

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,567 Previous Clinical Trials
10,911,635 Total Patients Enrolled
67 Trials studying COVID-19
1,438,444 Patients Enrolled for COVID-19
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,474 Previous Clinical Trials
8,092,803 Total Patients Enrolled
49 Trials studying COVID-19
1,427,221 Patients Enrolled for COVID-19

Media Library

PF-07817883 (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT05799495 — Phase 2
COVID-19 Research Study Groups: Arm 1: low dose, Arm 2: medium dose, Arm 4: Placebo, Arm 3: high dose
COVID-19 Clinical Trial 2023: PF-07817883 Highlights & Side Effects. Trial Name: NCT05799495 — Phase 2
PF-07817883 (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05799495 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for those over the age of seventy-five permissible in this experiment?

"As mandated by the inclusion criteria of this research project, only those aged 18-64 may apply."

Answered by AI

To whom is participation in this research opportunity accessible?

"This clinical trial requires patients to be between 18 and 64 years old, with an active diagnosis of covid-19. They are looking for approximately 228 volunteers."

Answered by AI

Has the FDA given its sanction to Arm 3: high dose?

"The safety of Arm 3: high dose was given a score 2 on the Power scale, as this is still in its Phase 2 trial and there is limited evidence supporting efficacy."

Answered by AI

How many individuals have been recruited for this clinical trial?

"This trial requires the enrolment of 228 qualified individuals. Those interested may participate from Proactive Clinical Research, LLC in Fort Lauderdale or Unlimited Medical Research Group based in Hialeah Gardens, Georgia."

Answered by AI

Are there any available positions in this research endeavor for participants?

"Affirmative. The data hosted on clinicaltrials.gov reveals that the trial, which was originally posted to the public domain on May 16th 2023, is actively seeking participants. Approximately 228 people have to be recruited from 10 distinct medical centres."

Answered by AI

To what extent have hospitals implemented this test program?

"Currently, 10 clinics are running this trial. The Fort Lauderdale area is well-represented with Hialeah Gardens and Hialeah plus other locations around the country. To lessen travel strain, it's advisable to pick a site that's in close proximity of your home."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
What site did they apply to?
ClinMed
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
2023. "A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05799495.
~125 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top